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Key Point Summary 
 SCFAs are bacterial metabolites produced during colonic fermentation of undigested 
carbohydrates, such as dietary fibre and prebiotics, and could mediate the interaction 
between diet, the microbiota and the host. 
 We quantified the fraction of colonic administered SCFA that could be recovered in the 
systemic circulation, the fraction that was excreted via breath and urine and the fraction 
that was used as a precursor for glucose, cholesterol and fatty acids. 
 This information is essential to understand the molecular mechanisms by which SCFA 
beneficially affect physiological functions such as glucose and lipid metabolism and 
immune function. 
 
Abstract 
The short-chain fatty acids (SCFAs), acetate, propionate and butyrate are bacterial 
metabolites that mediate the interaction between diet, the microbiota and the host. In this 
study, the systemic availability of SCFAs and their incorporation into biologically relevant 
molecules was quantified. Known amounts of 
13
C-labelled acetate, propionate and butyrate 
were introduced in the colon of 12 healthy subjects using colon delivery capsules and plasma 
levels of 
13
C-SCFAs and of 
13
C-glucose, 
13
C-cholesterol and 
13
C-fatty acids were measured. 
The butyrate producing capacity of the intestinal microbiota was quantified as well. Systemic 
availability of colonic-administered acetate, propionate and butyrate was 36%, 9% and 2%, 
respectively. Conversion of acetate into butyrate (24%) was the most prevalent 
interconversion by the colonic microbiota and was not related to the butyrate-producing 
capacity in the faecal samples. Less than 1% of administered acetate was incorporated into 
cholesterol and <15% in fatty acids. On average, 6% of colonic propionate was incorporated 
into glucose. The SCFAs were mainly excreted via the lungs after oxidation to 
13
CO2 whereas 
less than 0.05% of the SCFAs were excreted into urine. These results will allow future 
evaluation and quantification of SCFAs production from 
13
C-labelled fibres in the human 
colon by measuring 
13
C-labelled SCFA concentrations in blood. 
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Abbreviation list 
AUC, area under the curve; CDC: colonic delivery capsule; Cl, clearance; Css ,steady state 
concentration; cumPDR, cumulative percentage of administered dose; D, administered dose; 
FFAR, free fatty acid receptor; GC-C-IRMS, gas chromatography combustion isotope ratio 
mass spectrometry; GC-MS, gas chromatography mass spectrometry; GPR, G-protein 
coupled receptor; I, infusion rate; MCT, monocarboxylate transporter; OCTT, orocecal transit 
time; RT-PCR, real time polymerase chain reaction; SA, systemic availability; SCFA, Short-
chain fatty Acid; TCA, tricarboxylic acid; T20% , time of release of the CDC 
 
 
Body of paper 
Introduction 
Short chain fatty acids, mainly comprising acetate, propionate and butyrate are produced in 
the large intestine by microbial degradation of undigested carbohydrates and to a lesser extent 
proteins. They are increasingly recognised as signalling molecules that mediate the 
interaction between the diet, the gut microbiota and the host. Locally in the gut, SCFA are 
crucial for intestinal health because they serve as the major energy substrates for the 
colonocytes and because of their anti-inflammatory and anti-carcinogenic properties (Hamer 
et al., 2008). In addition, they affect gut and host metabolism by activating the G-protein 
coupled cell surface receptors GPR-41 and GPR-43 (Brown et al., 2003), later renamed as 
free fatty acid receptors (FFAR)-3 and FFAR-2, that are involved in the regulation of glucose 
and lipid metabolism (den Besten et al., 2013b). Activation of those receptors on the 
enteroendocrine L-cells in the colon results in the secretion of the gut-derived satiety 
hormones glucagon-like peptide 1 (GLP-1) and peptide YY (PYY), providing a mechanism 
for the beneficial effect of SCFA on energy intake and satiety (Canfora et al., 2015). Finally, 
a fraction of the colonic produced SCFA reaches the systemic circulation and directly affects 
the function and metabolism of peripheral organs and tissues such as the liver, the pancreas, 
adipocytes, immune cells and skeletal muscle tissue. As a consequence, SCFA have been 
involved in maintaining glucose and lipid metabolism and may provide an important target to 
tackle disorders that are associated with disturbances of glucose and lipid metabolism such as 
obesity, metabolic syndrome or type 2 diabetes. 
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To further understand how SCFAs provide a mechanistic link between the diet, the 
microbiota and health benefits, it is absolutely necessary to quantify the extent to which 
fermentation-derived SCFAs reach the systemic circulation. Quantitative information on the 
assimilation of SCFAs into biologically relevant molecules in humans may also contribute to 
unravelling the mechanism via which SCFAs elicit systemic effects. Currently, SCFAs are 
most often measured in faeces or in fasting blood samples. However, because of the rapid 
absorption of SCFAs by the colonocytes, only an estimated 5% of produced SCFAs is 
excreted in faeces (McNeil et al., 1978) rendering faecal measurements not representative for 
colonic SCFA production. In addition, the extensive metabolism in colonocytes and the liver 
results in low plasma levels of SCFAs. 
In this work, stable isotope technology was applied to determine the systemic availability of 
each SCFA after colonic administration of 
13
C-labelled SCFAs. The systemic availability is 
the fraction of an administered dose of unchanged substrate that reaches the systemic 
circulation. In addition, the occurrence of interconversions was evaluated and the 
incorporation of the colonic-derived 
13
C-SCFAs into glucose, free fatty acids and cholesterol 
was quantified. Stable isotope technology is a very sensitive analytical technique that allows 
measuring selectively in plasma those SCFAs that originate from the colon. 
 
Materials & Methods 
Ethical Approval 
The study procedure was approved by the Ethics Committee of the Leuven University 
Hospital, Leuven, Belgium. Written, informed consent was obtained from all subjects and the 
study conformed to the Declaration of Helsinki. The study was registered at 
ClinicalTrials.gov (NCT01757379). 
Colonic Delivery of SCFAs 
Known amounts of the individual 
13
C-labelled SCFAs (
13
C-acetate, 
13
C-propionate or 
13
C-butyrate) were delivered into the colon of healthy subjects using colon delivery capsules 
(CDCs). Hard gelatine capsules (size 0) were filled with either approximately 200 mg of 
13
C-labelled sodium acetate ([1-
13
C]acetate), 170 mg of 
13
C-labelled sodium propionate 
([1-
13
C]propionate) or 495 mg of 
13
C-labelled sodium butyrate ([1-
13
C]butyrate) (Euriso-top, 
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St Aubin, Cédex, France) together with 9.0% (w/w) citric acid (Sigma-Aldrich, Bornem, 
Belgium). The addition of citric acid was necessary to keep the pH of the capsule contents 
below pH 6.5 and to prevent in this way dissolution of the coating from the inside-out due to 
water intrusion into the capsules. Before and after filling, the capsules were weighed to 
determine their exact content. The capsules were coated manually with a pH-dependent film 
made up of Eudragit S100 (Evonik, Darmstadt, Germany) with diethyl phthalate (Omega 
Pharma, Nazareth, Belgium) (25% w/w with respect to polymer) as plasticizer. Eudragit S100 
only dissolves at a pH > 7.0 (Chourasia et al. 2003). The coating thickness was estimated 
from the increase in weight after coating and expressed in mg/cm² capsule surface. Coating 
thickness was varied between 13.5 mg/cm² and 23.3 mg/cm². 
Similar capsules containing 5.2 mg (in acetate capsules) or 4.0 mg (in propionate and 
butyrate capsules) methylene blue were prepared to assess the pH resistance of the polymer 
coating. The release of methylene blue from the coated capsules was monitored during in 
vitro dissolution tests in sodium phosphate buffers (0.1 M) of pH 6.3, 6.8, 7.0 and 7.2 
according to the USP XXV paddle method (150 rpm) at 37 °C. The concentration of the 
marker was quantified colorimetrically at 664 nm. All measurements were performed in 
duplicate. 
Study Design 
Twelve healthy subjects (7 F/ 5 M, aged 26 ± 6 years, BMI 22 ± 3 kg/m
2
) participated in a 
randomized cross-over study. Exclusion criteria were previous abdominal surgery (except 
from appendectomy), history of chronic gastro-intestinal conditions such as inflammatory 
bowel diseases, irritable bowel syndrome and celiac disease, or being on a low calorie or 
vegetarian diet. Female subjects were excluded if pregnant or lactating. All subjects were free 
of medication influencing the gut transit or intestinal microbiota for 14 days and of antibiotics 
for 1 month. Intake of pre- and probiotics was prohibited during the study period. Subjects 
were also excluded if they had donated blood during the last three months, suffered from low 
blood haemoglobin levels or had participated in experiments involving ionizing radiation 
during the last year. Each subject performed three test days (one type of SCFA per test day) 
with one week in between. During the three days prior to a test day, the subjects consumed a 
low-fibre diet and avoided alcohol intake. On the evening prior to the test day, a 
non-fermentable standard meal (lasagne) was offered to avoid changes in colonic 
fermentation during the different test days. In the morning of the test, the subjects received 
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two coated capsules containing either 
13
C-acetate, 
13
C-propionate or 
13
C-butyrate with a 
standard breakfast (pancake, 250 kcal) labelled with inulin-
14
C-carboxylic acid (74 kBq, 
American Radiolabelled Chemicals, St. Louis, MO, USA) as a marker for orocecal transit 
time (OCTT) (Verbeke et al., 2005). During each test day, a primed continuous intravenous 
infusion of deuterated SCFAs was applied ([
2
H3]-acetate: 10 µmol.kg
-1
 + 20 µmol.kg
-1
.h
-1
; 
[
2
H5]-propionate: 1 µmol.kg
-1
 + 2 µmol.kg
-1
.h
-1
; [
2
H7]-butyrate: 0.5 µmol.kg
-1
 + 1 µmol.kg
-
1
.h
-1
) to quantify the clearance of each SCFA. Before the breakfast and at regular time points 
during the day, breath, blood and urine samples were collected. Breath samples were 
collected every 20 min up to 10 h after breakfast. Blood samples were collected every hour 
during the first 4 h, every 20 min from 4 to 9 h and every 40 min from 9 h to 12 h. A basal 
urine sample and 0-4 h, 4-8 h, 8-12 h and 12-24 h urine fractions were collected in recipients 
containing neomycin to prevent bacterial growth. After 4 h and 8 h, the subjects received a 
standard non-fermentable meal (white bread with ham or cheese). Finally, all subjects 
delivered a faecal sample that within 10 h after collection was frozen at -80 °C until analysis.  
Analytical Procedures 
Analysis of Breath Samples. Measurements of 
13
CO2, H2 and 
14
CO2 in breath samples were 
performed as described previously (Verbeke et al., 2005). The results for 
13
CO2 were 
expressed as cumulative percentages of administered dose (cumPDR) (Braden et al., 2007). 
The time of release from the capsules (T20%) was defined as the time at which 20% of the 
cumPDR was recovered in breath. The cumPDR values after 12 h were corrected for 
13
CO2 
that is produced via oxidation but is not excreted using a correction factor of 0.55 as 
suggested by Maurer et al. (Maurer et al., 2013). The OCTT was defined as the time at which 
a significant increase in 
14
C from background was seen in breath, i.e. 2.5 times the standard 
deviation of all previous points above the running average of all previous points (Verbeke et 
al., 2005). 
Analysis of Total SCFA Concentrations in Plasma and Urine Samples. Total SCFA 
concentrations in plasma were measured using gas chromatography (GC) after purification 
and concentration of the samples with hollow fibre supported liquid membrane extraction as 
described by Zhao et al. (Zhao et al., 2007). To measure total SCFA concentrations in urine, 
samples (3.0 mL) were spiked with 150 µL internal standard mix (83 mg.L
-1
 2-ethyl-butyric 
acid and 200 mg.L
-1
 3-methyl-valeric acid) and 500 µL of 1.0 M sodium hydroxide and 
concentrated to dryness. After addition of 200 µL 37.0% HCl to the residue, SCFAs were 
  
 
This article is protected by copyright. All rights reserved. 
7 
 
extracted in 1.0 mL diethyl ether. The ether extracts were injected (0.5 µL) in pulsed splitless 
mode into the injector at 200 °C. Chromatographic analysis was carried out on a fused-silica 
capillary column with Free Fatty Acid Phase (DB-FFAP 125–3237, J&W Scientific, Agilent 
Technologies, Santa Clara, California, USA) of 30 m × 0.53 mm i.d. coated with 0.50 µm 
film thickness using an Agilent 6890N GC system equipped with a flame ionization detector 
(Agilent Technologies). Column temperature was started at 100 °C (3 min) and increased to 
140 °C (5 min) at a rate of 4 °C/min followed by an increase to 235 °C (5 min) at a rate of 
40 °C/min. Helium was used as carrier gas in a constant flow mode of 4.2 mL/min and the 
detector temperature was set at 240 °C. The flow rates of the detector gases hydrogen, air and 
nitrogen as makeup gas were 30, 300 and 20 mL/min, respectively. Data handling was carried 
out with a HP ChemStation Plus software (B.04.03, Agilent Technologies). 
Analysis of 
13
C- and 
2
H-enrichments of SCFA in Plasma and Urine Samples. Plasma 
samples were deproteinised and extracted according to Morrison et al. (Morrison et al., 2004) 
whereas urine samples were only dried and extracted. The extracted samples for analysis of 
13
C-enrichment of SCFAs were injected (4 µL) in splitless mode at 240 °C into a Delta-XP 
isotope ratio mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) equipped with 
a Trace gas chromatograph and a combustion interface type 3 (GC-C-IRMS). An 
AT-Aquawax-DA column (30 m x 0.53 mm i.d. and 1.00 µm film thickness; Grace, Lokeren, 
Belgium) was used. The initial oven temperature was 80 °C (3 min) and ramped to 140 °C at 
a rate of 4 °C/min followed by an increase to 240 °C (10 min) at a rate of 16 °C/min. Helium 
was used as carrier gas in a constant flow mode of 2.5 mL/min. After elution from the GC 
column, the compounds were oxidized into CO2 in the combustion reactor after which the 
enrichment was measured in the IRMS detector. To calculate the enrichment of the SCFAs 
from the measured 
13
CO2 enrichment, the number of labelled carbon atoms per molecule and 
the enrichment of the administered substrate (
13
C-SCFAs) were taken into account. Data were 
processed using Isodat NT (version 2.0, Finnigan™, Thermo Fisher Scientific).  
For the analysis of the 
2
H-enrichments of SCFAs, 1 µL of the extracted samples was injected 
at 240 °C in splitless mode into the injector of a gas chromatograph equipped with a 
quadrupole system (Trace GC Ultra and DSQ II, Thermo Electron Corporation, Waltham, 
MA, USA) with an AT-Aquawax DA column (30 m x 0.25 mm i.d. and 0.25 µm film 
thickness; Grace). The initial oven temperature was 40 °C (3 min) and ramped to 140 °C at a 
rate of 4 °C/min followed by an increase to 240 °C (6 min) at a rate of 16 °C/min. Helium 
was used as carrier gas in a constant flow mode of 1 mL/min. The transfer line was 
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maintained at 240 °C. The mass spectrometer was operated in full scan monitoring mode (m/z 
33-650) and the source temperature was set at 250 °C. Xcalibur
TM
 software (Thermo Fisher 
Scientific) was used for the automatisation of the GC-MS system and for data acquisition. 
Analysis of 
13
C-glucose. Total plasma glucose concentrations and 
13
C-glucose enrichments 
were measured using GC-C-IRMS after derivatization of glucose to its aldonitrile penta 
acetate derivative according to Schierbeek et al. (Schierbeek et al., 2009). The derivatized 
samples were injected (1 µL) in splitless mode into the GC-C-IRMS instrument equipped 
with an AT-5ms capillary column (30 m x 0.32 mm i.d. and 1.0 µm film thickness; Grace). 
The injector temperature was set at 250 °C and the initial oven temperature amounted to 
95 °C (30 s) and was increased to 300 °C (15 min) at 20 °C/min. The helium carrier flowed at 
a constant rate of 1.5 mL/min. To calculate the enrichment of 
13
C-glucose from the measured 
enrichment of 
13
CO2, it was assumed that one propionate molecule was incorporated per 
glucose molecule.  
Analysis of 
13
C-free fatty acids. The concentrations and 
13
C-enrichment in plasma of palmitic 
(C16:0), stearic (C18:0) and oleic (C18:1, n-9) acid were measured using GC-C-IRMS after 
prior conversion of the fatty acids into their corresponding methyl esters as described by 
Wang et al. (Wang et al., 2012). Samples were injected (1 µL) at 250 °C in a splitless mode 
into an AT-aquawax-DA column (30 m x 0.53 mm i.d. and 1.0 μm film thickness; Grace). 
The initial oven temperature was 50 °C (2 min) and ramped to 200 °C (10 min) at a rate of 
10 °C/min followed by an increase to 220 °C (15 min) at a rate of 10 °C/min. Helium was 
used as carrier gas in a constant flow mode of 2.5 mL/min. To calculate the enrichment of 
13
C-fatty acids from the measured enrichment of 
13
CO2, we assumed that one acetate 
molecule was incorporated per fatty acid molecule. 
Analysis of 
13
C-cholesterol. Plasma samples for 
13
C-enrichment measurements of cholesterol 
were saponified and extracted in sequence with hexane and diethyl ether according to Paik et 
al. (Paik et al., 2008). The supernatant layer was silylated using 
N,O-bis(trimethylsilyl)trifluoroacetamide. The 
13
C-enrichment of cholesterol in plasma 
samples was measured using GC-C-IRMS analysis with an Rxi-5ms capillary column (30 m 
× 0.25 mm i.d. and 0.5 µm film thickness; Interscience, Breda, The Netherlands). Samples 
were injected (1 µL) in splitless mode at 250 °C into the column. The initial oven temperature 
was 240 °C (1 min) and was increased to 300 °C (15 min) at 20 °C/min. Helium gas was used 
as carrier gas and flowed at a constant rate of 2.5 mL/min. To calculate the enrichment of 
13
C-cholesterol from the measured enrichment of 
13
CO2, it was assumed that one acetate or 
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propionate molecule was incorporated per cholesterol molecule. Total cholesterol 
concentrations were determined using standard laboratory techniques.  
Analysis of Butyrate-producing Capacity in Faecal Samples. Real-time PCR was used to 
quantify Clostridium cluster IV, Clostridium cluster XIV, butyryl-CoA:acetate-CoA 
transferase and butyrate kinase genes in faecal samples as described previously (Boets et al., 
2015). 
Calculations 
Systemic availabilities of colonic acetate, propionate and butyrate. The systemic availability 
of each SCFA was determined by measuring 
13
C-acetate, 
13
C-propionate and 
13
C-butyrate 
plasma concentrations up to 12 h after colonic delivery of 
13
C-acetate, 
13
C-propionate and 
13
C-butyrate, respectively, on three separate test days. At each time point, total 
(labelled + unlabelled) SCFA concentrations and 
13
C-SCFA enrichments were measured. The 
plasma concentration of 
13
C-SCFAs consists of the concentration of 
13
C-SCFAs naturally 
present in the plasma and the concentration originating from the colon. The concentration of 
13
C-SCFAs originating from the colon at each time point (ncolon) was calculated according to 
equation 1 and allowed constructing 
13
C-SCFA concentration versus time graphs: 
                
                  
                   
 (equation 1) 
with ntot: total concentration of SCFAs (labelled + unlabelled), APtot: 
13
C-enrichment of the 
SCFAs measured in plasma at time point t, AP plasma t0: 
13
C-enrichment of the SCFAs 
measured in plasma at time 0, and APcolon: 
13
C-enrichment of the administered substrate. 
To allow calculating the clearance of the SCFAs, a primed constant infusion with 
2
H-SCFAs 
was applied during each test day. The 
2
H-enrichments of the SCFAs were multiplied with the 
SCFA plasma concentrations to calculate the 
2
H-SCFA concentrations. Subsequently, the 
clearance (Cl, L.h
-1
) was calculated from the 
2
H-SCFA infusion rate (I2H-SCFA, µmol.h
-1
) and 
the steady state 
2
H-SCFA plasma concentration (Css, µmol.L
-1
) according to equation 2: 
     
 
       
   
 (equation 2) 
13
C-SCFA concentration versus time graphs were used to calculate the exposure to 
13
C-SCFAs in plasma using the trapezoidal rule. Finally, knowing the administered amount of 
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each 
13
C-SCFA, the systemic availability of 
13
C-acetate, 
13
C-propionate and 
13
C-butyrate was 
calculated according to equation 3: 
        
            
        
      (equation 3) 
with SA: systemic availability (%), AUC: area under the curve of the 
13
C-SCFA 
concentration versus time graph (µmol.h.L
-1
), Cl: clearance of the respective SCFA (L.h
-1
), 
and Dcapsule: administered dose of the respective SCFA (µmol). 
Assimilation of SCFAs into biologically relevant molecules. The fraction of colonic-derived 
propionate used for glucose production was quantified from the cumulative amount of 
13
C-glucose appearing in the plasma after colonic administration of 
13
C-propionate according 
to equation 4. 
                                 
               
               
      (equation 4) 
with F13C-label recovered as glucose: the fraction of administered 
13
C recovered in glucose (%), AUC: 
the area under the curve of the 
13
C-glucose versus time graph (µmol.h.L
-1
), Clglucose: the 
clearance (L.h
-1
) of glucose that was calculated for each individual according to Jani et al. 
(Jani et al., 2008) and amounted to 8.9 ± 1.2 L.h
-1
, and D13C-propionate: the dose of colonic 
administered 
13
C-propionate (µmol). 
Similarly, the fraction of 
13
C-acetate incorporated into the most abundant fatty acids 
(palmitic, stearic and oleic acid) was calculated according to equation 4 using the respective 
AUCs of the 
13
C-fatty acids versus time graphs, the clearance of palmitic, stearic and oleic 
acid, respectively, and the administered dose of 
13
C-acetate. The clearance of the fatty acids 
was obtained from literature and amounted to 48, 30 and 45 L.h
-1
 for palmitic, stearic and 
oleic acid, respectively. 
Finally, the extent to which intestinal acetate and propionate were used for de novo synthesis 
of cholesterol was determined. The fractional incorporation of 
13
C-acetate and 
13
C-propionate 
into cholesterol was calculated according to equation 4 using the AUC of the 
13
C-cholesterol 
versus time graph, the clearance of cholesterol and the administered dose of 
13
C-acetate and 
13
C-propionate, respectively. The clearance of cholesterol was calculated for each individual 
based on his/her body weight and cholesterol levels as described by Turner et al. (Turner et 
al., 2012) and amounted to 0.15 ± 0.04 L.h
-1
. 
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Statistical analysis 
Statistical analyses were performed using SPSS, version 22.0 (IBM Corp, New York, USA). 
All results are presented as means ± standard deviations (SDs). Assumptions of normality 
were checked with a Shapiro-Wilk test. The OCTT and time of 
13
CO2 in breath samples were 
compared with a paired samples T-test. Bivariate correlations were performed with 
Spearman’s rho. Significance was accepted at the 5% level.  
 
Results 
Delivery of SCFAs into the colon of healthy subjects 
In vitro dissolution tests indicated an appropriate release profile of the marker methylene blue 
from the CDCs (release after 45 min at pH = 7.0) with a coating thickness of 18.8 mg/cm² 
capsule surface (Figure 1 A).  
To evaluate the in vivo performance of the capsules, the time at which 
13
CO2, resulting from 
oxidation of released 
13
C-SCFAs, appeared in breath was compared with the OCTT which 
was estimated from an increase of 
14
CO2 in breath (Verbeke et al., 2005). A simultaneous 
increase in breath of 
13
CO2 and 
14
CO2 indicates a correct release of the CDCs content in the 
proximal colon (Figure 1 B). No significant differences were observed between the 
13
CO2 
excretion time (383 ± 105 min) and the OCTT (399 ± 84 min) in any of the test days 
(p = 0.202) (Figure 1 C).  
Systemic availabilities of colonic acetate, propionate and butyrate 
13
C-SCFA concentration versus time graphs were constructed for the three test days of each 
subject and a representative example is shown Figure 2 A. By calculating the area under these 
13
C-SCFA concentrations versus time graphs an exposure of 1.92 ± 1.13, 0.48 ± 0.26 and 
0.21 ± 0.20 µmol.h.L
-1 
was obtained for 
13
C-acetate, 
13
C-propionate and 
13
C-butyrate, 
respectively. Total body clearance of acetate, propionate and butyrate amounted to 938 ± 287, 
647 ± 176 and 1237 ± 592 L.h
-1
, respectively. On average, the fraction of colonic-derived 
acetate, propionate and butyrate appearing in plasma amounted to 36 ± 21%, 9.2 ± 5.9% and 
2.4 ± 1.9%, respectively (Figure 2 B).  
SCFAs are interconverted by gut microbiota 
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The individual 
13
C-SCFAs were administered on separate days to allow evaluating the extent 
of interconversion between the three SCFAs. After administration of 
13
C-acetate, the extent 
of its conversion into 
13
C-propionate and 
13
C-butyrate was determined by quantifying the 
appearance of 
13
C-propionate and 
13
C-butyrate in plasma. Interconversion was quantified in 
similar ways after administration of 
13
C-propionate and 
13
C-butyrate. The incorporation of 
13
C-acetate into butyrate (Figure 3 A) was quantitatively the most significant interconversion 
but all interconversions were detected. To confirm that conversion of acetate into butyrate 
was due to bacterial and not to human metabolism, uncoated 
13
C-acetate capsules were 
administered. As these released 
13
C-acetate already in the proximal gastrointestinal tract, 
13
C-acetate was absorbed before it had been in contact with bacteria and appeared in plasma 
already after 120 min. No 
13
C-butyrate in plasma was observed, confirming that contact with 
bacteria is essential for the interconversion to occur (Figure 3 B and 3 C). 
Quantification of the butyrate-producing capacity of the intestinal microbiota 
To relate the interconversion of acetate into butyrate to the intestinal microbiota composition 
of the subjects, the butyrate-producing capacity in a faecal sample was quantified. RT-PCR 
was used to quantify genes coding for butyrate kinase and butyryl-CoA:acetate 
CoA-transferase which are the dominant terminal enzymes in the production of butyrate 
(Louis & Flint, 2007; Vital et al., 2013). In addition, the most abundant clusters of butyrate 
producing bacteria, i.e. Clostridium clusters IV and XIVa, were quantified (Figure 4 A). 
However, the extent of acetate into butyrate conversion was not significantly related to any of 
these parameters of butyrate-producing capacity (Figure 4 B-E).  
Utilization of colonic-derived propionate in gluconeogenesis 
Plasma 
13
C-glucose concentrations increased simultaneously with 
13
C-propionate 
concentrations (Figure 5 A). The cumulative amount of 
13
C-glucose was 
23 ± 20.5 µmol.h.L
-1
. We calculated that 5.9 ± 4.7% of the colonic administered propionate 
was used for gluconeogenesis (Figure 5 B). 
Incorporation of acetate into fatty acids  
The 
13
C-enrichment and total concentrations of the most abundant plasma fatty acids, 
palmitic acid (C16:0), stearic acid (C18:0) and oleic acid (C18:1, n-9) were quantified after 
13
C-acetate administration. Enrichment was mainly observed in palmitic acid and to a lesser 
extent in stearic and oleic acid (Figure 5 C). Up to 12.0 ± 8.7%, 1.0 ± 0.9% and 1.0 ± 1.0% of 
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administered acetate was assimilated into palmitic, stearic and oleic acid, respectively (Figure 
5 D). 
Incorporation of colonic-derived acetate and propionate into cholesterol 
After administration of 
13
C-acetate, 
13
C-cholesterol readily appeared in plasma whereas 
13
C-cholesterol was hardly detectable after administration of 
13
C-propionate (Figure 5 E). 
Only 0.101 ± 0.076% and 0.007 ± 0.005% of administered 
13
C-acetate and 
13
C-propionate 
were assimilated into cholesterol, respectively (Figure 5 F). 
Conversion of short-chain fatty acids into carbon dioxide 
The extent to which 
13
C-substrates are converted to 
13
CO2 at the whole-body level is most 
often estimated from the excretion of 
13
CO2 in breath. After 12 h, the cumulative percentage 
of 
13
C-label recovered as 
13
CO2 in breath after administration of 
13
C-propionate amounted to 
47 ± 13%, whereas 33 ± 10% of administered 
13
C-acetate and 18 ± 3% of administered 
13
C-butyrate was recovered (Figure 6). Application of the correction factor for the 
13
CO2 that 
is retained in the body indicated that up to 86 ± 24% of administered 
13
C-propionate, 
60 ± 18% of administered 
13
C-acetate, and only 33 ± 6% of administered 
13
C-butyrate was 
oxidized into 
13
CO2 within 12 h.  
Urinary excretion 
Subjects collected urine for 24 h in different fractions (0-4 h, 4-8 h, 8-12 h, 12-24 h) to allow 
quantification of the urinary excretion of 
13
C-SCFAs. After 24 h, only up to 0.031 ± 0.020% 
of 
13
C-acetate, 0.008 ± 0.002% of 
13
C-propionate and 0.0006 ± 0.0003% of 
13
C-butyrate were 
retrieved in urine. 
 
Discussion 
By applying a direct, stable isotope based approach, the present study enabled to provide 
quantitative information on the uptake and elimination of SCFAs in different body 
compartments and their assimilation into biologically relevant molecules in humans. This 
information may contribute to deciphering the mechanistic link between fibre consumption 
and its health benefits.  
Colonic delivery of SCFA 
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Targeting of orally administered compounds to the colon can be achieved using various 
strategies including the use of coatings with a pH-sensitive polymer, formulation of time-
released systems, use of carriers that are specifically degraded by colonic bacteria, covalent 
linkage of the compound with a carrier, bioadhesive systems and osmotic controlled drug 
delivery systems (for a review, see Charousia et al., 2003). These formulations have been 
mainly developed to target drugs to the colon either for treatment of local diseases such as 
Crohn’s disease or ulcerative colitis but also because of the potential to deliver therapeutic 
peptides or proteins. Due to absence of peptidases in the colon, peptide drug might be 
absorbed unchanged after peroral administration. Targeted delivery of SCFA to the colon has 
previously been achieved using carriers such as starch (Annison et al. 2003) or inulin 
(Chambers et al., 2014). Upon arrival in the colon, the carriers are fermented by the resident 
bacteria and release the SCFA that are attached to them. We preferred to use gelatine 
capsules with a pH-dependent coating as a convenient vehicle to deliver well known amounts 
of SCFA to the colon. 
Systemic availability of SCFAs 
Estimates of the extraction of the SCFAs during passage through the splanchnic bed have 
been reported and are based either on differences in SCFA concentrations in peripheral blood 
compared to their concentrations in portal blood obtained during abdominal surgery (Peters et 
al., 1992; Bloemen et al., 2009) or on isotope dilution experiments (Pouteau et al., 1996). 
Estimates for splanchnic extraction of acetate vary from 40-75% (Pouteau et al., 1996; Vogt 
et al., 2004) whereas an extraction value of 90% for propionate has been mentioned (Vogt et 
al., 2004). As butyrate is the preferred energy source for colonocytes, the majority of 
absorbed butyrate may already be consumed by the colonic mucosa. According to Cook and 
Sellin (1998), 70-90% of butyrate is metabolized in the colonocytes (Cook & Sellin, 1998). 
Bloemen et al. showed that the release of butyrate from the liver is not significantly different 
from zero, suggesting a splanchnic extraction of almost 100% (Bloemen et al., 2009). Of 
note, all studies mention a wide interindividual variation in SCFA levels, both in peripheral 
and in portal blood (Peters et al., 1992; Bloemen et al., 2009). 
We combined colonic administration of 
13
C-labelled SCFA with intravenous administration 
of 
2
H-labelled SCFA to determine the SCFA systemic availability, assuming a similar 
behaviour of both types of labelled SCFA. Although simultaneous infusion of 
13
C-acetate and 
2
H-acetate in the gut of pigs resulted in higher 
13
C-acetate than 
2
H-acetate enrichment in 
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plasma, suggesting in vivo isotope exchange of the deuterium hydrogen atoms in acetate and 
thus underestimation of the deuterium enrichment (Kien et al., 1996), we did not find 
evidence for such isotope exchange in our study. Indeed, the ion masses used to quantify 
acetate and 
2
H3-acetate were m/z 60 and 63, respectively, with no quantifiable ions at mass 
m/z 61 nor 62. Similarly, we did not find evidence for isotope exchange of 
2
H7-butyrate 
which was quantified using a fragment ion with m/z of 63, rather than the parent ion. 
Therefore, even if isotope exchange occurred in the remaining part of the molecule, which we 
cannot exclude, this will not have affected our results. 
2
H5-propionate was quantified using 
the parent ion at m/z 79. Although smaller peaks at m/z 78 and 77 were visible suggesting 
isotope exchange, the same ratios were observed in the infusion solution as in the plasma 
samples indicating that the exchange likely occurred in the ion source of the mass 
spectrometer rather than in vivo. 
The values for systemic availability of acetate (36%) and propionate (9%) obtained in this 
study correspond to a splanchnic extraction of 64% and 91%, respectively, which is in nice 
agreement with reported values. Also in the present study, a large interindividual variation 
was observed. In addition, the direct stable isotope approach enabled detecting 
13
C-butyrate 
in plasma after colonic administration of 
13
C-butyrate and to quantify its systemic availability 
(2%) or splanchnic extraction (98%).  
Metabolism of SCFAs 
Within 12 h after colonic administration, the vast majority of propionate (86%) was 
converted into CO2 of which 47% was recovered in breath. The remainder was retained in the 
body bicarbonate pool. Except from being a substrate for gluconeogenesis, no other pathways 
for incorporation of propionate into other metabolites are known and the fate of propionate 
seems to be a rapid and almost complete conversion into CO2, which proceeds most likely in 
the liver. These results do not allow differentiating between the fraction of propionate that is 
directly converted into CO2 and that used for gluconeogenesis followed by oxidation of the 
resulting glucose into CO2. After administration of 
13
C-acetate, recovery in breath was lower 
compared to that of 
13
C-propionate. This may be explained by labelled C that does not appear 
as 
13
CO2 but is exchanged in other metabolites. These are most likely metabolites of the 
tricarboxylic acid (TCA) cycle (van Hall, 1999), as acetate enters the TCA cycle after 
conversion into acetyl-CoA. This exchange is only temporary since the resulting metabolites 
re-enter the oxidative pathways at a later time. This also explains the observation that breath 
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13
CO2 recoveries after intravenous 
13
C-acetate infusion increase with the duration of the 
infusion and only reach a plateau after 12 h of infusion (Mittendorfer et al., 1998). Breath 
13
CO2 recoveries after colonic administration of 
13
C-acetate have not been reported in 
literature. Reported 
13
CO2 recoveries after intravenous 
13
C-acetate administration vary from 
40% to 81% (Wolfe & Jahoor, 1990; Pouteau et al., 1996; Mittendorfer et al., 1998). 
The low recovery of 
13
CO2 after administration of 
13
C-butyrate (33%) is probably in part due 
to exchange of the label into TCA metabolites. After absorption in the colonocytes, butyrate 
is taken up in the mitochondria of the cells where it undergoes the β-oxidation pathway, 
which involves a series of five enzymes, to form acetyl-CoA that subsequently enters the 
TCA cycle (De Preter et al., 2012). A few other studies that compared the rate of colonic 
butyrate oxidation in patients with ulcerative colitis and healthy controls, report on 
13/14
CO2 
recoveries in breath after colonic administration of 
13
C- or 
14
C-labelled butyrate. Six hours 
after rectal instillation of 
14
C-butyrate enemas, 52.9 (44.4-61.5)% of administered label was 
retrieved in breath (Den Hond et al., 1998). In another study, about one fourth of rectally 
instilled 
13
C-butyrate was recovered as 
13
CO2 after 4 hours (Simpson et al., 2000). After 
intravenous infusion of 
13
C-butyrate in five healthy subjects, the 6-h cumulative excretion of 
13
CO2 amounted to 49.9 ± 2.2% (Den Hond et al., 1998). For all 
13
C-SCFA, higher fractions 
of administered dose are excreted in breath as 
13
CO2 than appearing in plasma indicating that 
they are metabolized prior to arrival in the systemic circulation, i.e. presumably in the 
colonocytes and liver. 
In the human kidney, monocarboxylate transporters (MCTs) are responsible for the 
reabsorption of SCFAs and ketone bodies (Halestrap & Meredith, 2004). Although lactate is 
quantitatively the most important substrate for these transporters, they have been shown to 
also reabsorb SCFAs. As a consequence, urinary excretion of SCFAs is low. After continuous 
infusion of sodium butyrate for 10 days in patients with acute leukaemia, only 0.21 ± 0.04‰ 
of the administered dose was retrieved in urine (Miller et al., 1987). In healthy subjects, 
urinary levels of SCFA have been reported in a range of 0.8-130 µM for acetate and below 
3 µM for propionate and butyrate (Perry et al., 1970).  
In vivo cross-feeding 
Cross-feeding involves the supply of breakdown products of carbohydrates after partial 
hydrolysis by primary degraders as secondary substrates to other bacteria (De Vuyst & Leroy, 
2011). In particular, acetate is known to function as an intermediate in cross-feeding 
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interactions between colon bacteria, and plays a key role in colonic butyrate production 
(Morrison et al., 2006; Riviere et al., 2015). Morrison et al. incubated human faecal slurries 
in vitro with 
2
H-labelled SCFAs and quantified the interconversion between the SCFAs 
(Morrison et al., 2006). After 6 h, 0.28 mol/mol labelled acetate was incorporated into 
butyrate. In the present study, conversion of 
13
C-acetate into 
13
C-butyrate was estimated to be 
about 24%. Although the contact time of 
13
C-acetate with the intestinal microbiota was 
shorter in vivo than in vitro as 
13
C-acetate was rapidly absorbed into the plasma after release 
from the CDCs, the value is only slightly lower than the Morrison data, suggesting that this 
interconversion proceeds quite rapidly. Whereas no evidence for incorporation of 
2
H-acetate 
into propionate or 
2
H-propionate into butyrate was found in the in vitro study, all possible 
interconversions could be detected, albeit to a lower extent than the acetate-into-butyrate 
interconversion. This discrepancy is likely due to the different analytical techniques used in 
both studies. Morrison et al. applied GC-MS analysis which allowed differentiating between 
different isotopomers of the SCFAs, but is a less sensitive technique than the isotope ratio 
mass spectrometry applied in the present study. In a recent study in mice, enrichments of 
cecal SCFAs were quantified after a 6-h cecal infusion of 
13
C-labelled SCFA. A high 
conversion was observed from acetate into butyrate, a low conversion from butyrate into 
acetate and between butyrate and propionate and very little interconversion between acetate 
and propionate (den Besten et al., 2013a). 
Propionate as a substrate for gluconeogenesis 
Studies in lactating cows report that up to 61% of glucose in blood is derived from 
gluconeogenesis with propionate as the substrate (Wiltrout & Satter, 1972). In sheep, 
corresponding values between 42% and 59% have been reported (Leng et al., 1967). On the 
other hand, up to 32% of colonic-derived propionate is incorporated into glucose in sheep and 
up to 62% in mice (Leng et al., 1967; den Besten et al., 2013a). Compared to those values, 
the extent of incorporation of colonic-derived propionate into glucose (5.9%) is limited in 
humans, as shown by the present study. Indeed, propionate is the major substrate for 
gluconeogenesis in ruminants (Bergman, 1990) whereas in humans, lactate and pyruvate are 
the major gluconeogenic substrates with minor contributions of alanine and glycerol (Garber 
et al., 1974). Several methods based on stable isotope technology have quantified in vivo the 
contribution of gluconeogenesis to the glucose production in humans (Previs & 
Brunengraber, 1998). However, contributions of all gluconeogenic substrates are included in 
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these estimates and no human data on the contribution of propionate to gluconeogenesis are 
available.  
More recently, it has been shown in rats that propionate is incorporated into glucose at the 
level of the intestine (De Vadder et al., 2014). The resulting glucose is sensed in the walls of 
the portal vein and induces a nervous signal to the brain that influences food intake and 
glucose homeostasis. These results may provide a mechanistic role for propionate in the 
beneficial effects of dietary fibre. Unfortunately, due to inability to obtain portal blood from 
healthy subjects, our results do not allow determining whether the observed incorporation of 
13
C-propionate into glucose occurs in the intestine or in the liver.  
Incorporation of acetate into fatty acids 
Indirect methods to estimate de novo lipogenesis such as indirect whole-body calorimetry as 
well as direct methods such as 
2
H2O infusion and mass isotopomer distribution analysis 
(MIDA) confirmed that de novo lipogenesis (DNL) is a quantitatively minor pathway under 
normal conditions of typical high-fat diets (Hellerstein et al., 1991; Hellerstein et al., 1996; 
Bjorntorp and Sjostrom, 1978). Absolute DNL was estimated at less than 1 g synthesized per 
day which is low compared to a dietary fat intake of typically 100 g per day (Hellerstein et 
al., 1996). Studies using MIDA intravenously infuse 
13
C-acetate to enrich the acetyl-CoA-
precursor pool and express the fractional hepatic DNL as fraction of newly synthesised lipid 
compared to the lipid already present and not as fraction of administered acetate incorporated 
in the lipid. As a consequence, it is not possible to compare the results obtained in the present 
study to those results reported in literature. Almost 15% of colonic-administered acetate was 
incorporated into fatty acids in the present study. However, this only corresponds to an 
absolute amount of 0.229 ± 0.175 g of newly synthesized fatty acids which is still far below 
the 1 g threshold. It needs to be taken into account that only 5 mmol of 
13
C-labelled acetate 
was administered in the colon delivery capsules whereas the amount of acetate produced in 
the colon on a western diet (20 g of dietary fibre) has been estimated at about 150 mmol per 
day (Wolever et al., 1995). 
Incorporation of acetate and propionate into cholesterol 
It has been calculated that the rate of de novo synthesis of cholesterol amounts to 
10 ± 6 mg.kg
-1
.day
-1
 in healthy adults (Renfurm et al., 2004). As the biosynthesis of 
cholesterol starts from the two-carbon acetate group of acetyl-CoA, it has been suggested that 
dietary fibres that are fermented into a high proportion of acetate might increase serum 
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cholesterol levels. However, unlike propionate and butyrate, the majority of plasma acetate 
originates from endogenous metabolism and the contribution of colonic-derived acetate to 
cholesterol synthesis may well be less important. Indeed, the present study showed that less 
than 0.1% of colonic-administered acetate was incorporated into cholesterol. This value is of 
the same order of magnitude as the value of 0.7% reported by Hellman et al. after oral 
administration of 
14
C-acetate (Hellman et al., 1954). In mice, the fractional synthesis of 
cholesterol from acetate was 0.7 ± 0.1% (den Besten et al., 2013a). Propionate did not 
contribute to cholesterol synthesis neither in this study nor in the study in mice mentioned 
before (den Besten et al., 2013a). 
Limitations of the present study 
For the calculation of the systemic availability, it was assumed that the absorption of the 
13
C-SCFAs from the colonic lumen was quantitative. The major part of SCFA is transported 
in dissociated form across the apical membrane of the colonocytes by the monocarboxylate 
transporter 1 (MCT-1), the electrogenic sodium dependent monocarboxylate transporter 1 
(SMCT-1) or an SCFA-HCO3
-
 exchanger of unknown identity (den Besten et al., 2013).  It is 
indeed generally believed that the colon has a large capacity to absorb SCFAs with estimates 
of 6.1-12.6 µmol/cm².h (He et al., 2006). As the human colon has a mucosal surface area of 
about 20000 cm² (Helander & Fandriks, 2014), up to 120-250 mmol of SCFAs could be 
absorbed per hour. To confirm a quantitative SCFA absorption, a complete stool collection 
for 3-5 days after each test day would have been required for quantifying residual 
13
C-SCFAs. This would have placed an additional burden on the protocol which was already 
onerous for the participants and was therefore not performed. Only one stool sample was 
collected for the analysis of the microbial butyrate-producing capacity. 
In this study, the metabolic fate of the SCFA was evaluated in standardized feeding 
conditions (i.e. after administration of a non-fermentable standard breakfast and lunch). 
Whether the oxidation and/or incorporation of SCFA in biomolecules differs in fasting 
conditions remains to be investigated. 
 
Conclusions 
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The setup and methodology used in the present study allowed quantifying the percentages of 
acetate, propionate and butyrate originating from the colon that reached the systemic 
circulation. In addition, the metabolism and assimilation of acetate, propionate and butyrate 
into biologically relevant molecules were measured.  
In the future, these results will allow evaluating and quantifying SCFA production of varying 
13
C-labelled fibres in the human colon by measuring 
13
C-labelled SCFA concentrations in 
blood and multiplying the amounts of SCFAs that reached the plasma with the systemic 
availability index calculated in this study. In addition, the availability of plasma clearance 
values for each SCFA will allow calculating fluxes under different conditions when 
combined with plasma SCFA measurements. 
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Figure legends 
Figure 1: In vitro and in vivo evaluation of the performance of the colon delivery capsules. (A) In vitro 
dissolution profile of colon delivery capsules at different pH, n = 2. (B) A representative example of 
the appearance of 14CO2 and 
13CO2 in breath after administration of 
13C-acetate colon delivery 
capsules. The simultaneous rise in breath of 14CO2 and 
13CO2 indicates a correct delivery of 
13C-
acetate in the colon. (C) Comparison of the time of release of the 13C-SCFAs from the capsules 
(indicated by the time point at which 20 % of the cumulative amount recovered was obtained, t20%) 
and arrival of the test meal in the colon (indicated by the orocecal transit time, OCTT), n = 36 except 
for OCTT n = 30. Results are expressed as means and standard deviations. 
Figure 2: Calculation of the systemic availability of colonic-administered 13C-SCFAs. Typical graph 
depicting (A) 13C-acetate concentrations in plasma versus time. (B) Systemic availability results of 
acetate, propionate and butyrate for all 12 subjects. Results are expressed as means and standard 
deviations. 
Figure 3: Cross-feeding of SCFAs. (A) Overview and quantitative indication of the interconversions 
between acetate, propionate and butyrate, n = 12. (B) Appearance of 13C-acetate in plasma after 
administration of a coated and uncoated capsule filled with 13C-acetate. Without coating, 13C-acetate 
was released in the proximal intestine and appears at an earlier time in plasma compared to a 
coated capsule. (C) Appearance of 13C-butyrate in plasma after administration of a coated and 
uncoated capsule filled with 13C-acetate. 13C-butyrate is only formed when 13C-acetate is properly 
released in the colon. 
Figure 4: Butyrate-producing capacity. (A) Gene copy numbers of butyrate-producing colon bacteria 
and butyrate-producing colon enzymes in faecal samples, n = 11. (B-C) Correlation between acetate-
into-butyrate conversion and enzymes involved in butyrate synthesis, n = 11. (D-E) Correlation 
between acetate-into-butyrate conversion and the most abundant butyrate-producing bacteria, 
n = 11. 
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Figure 5: Assimilation of 13C-SCFAs in biologically relevant molecules. (A) Typical example that shows 
the appearance of 13C-propionate followed by 13C-glucose in plasma after colonic administration of 
13C-propionate. (B) Fraction of administered 13C-propionate recovered in glucose, n = 12. (C) Typical 
example that shows the appearance of 13C-acetate followed by 13C-palmitate, 13C-stearate and 
13C-oleate in plasma after colonic administration of 13C-acetate. (D) Fraction of administered 
13C-acetate recovered in palmitate (C16), stearate (C18) and oleate (C18:1), n = 12. (E) Typical 
examples that show the appearance of 13C-acetate and 13C-propionate followed by 13C-cholesterol in 
plasma after colonic administration of 13C-acetate. (F) Fraction of administered 13C-acetate and 
13C-propionate recovered in cholesterol, n = 12. Results are expressed as means and standard 
deviations. 
Figure 6: Recovery of 13C-acetate, 13C-propionate and 13C-butyrate in breath as 13CO2. Results 
are expressed as means and standard deviations, n = 12. 
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